Hi,
let me use an example text for mgt of endometrial hyperplasia.
the text is at bottom.
i asked chatgpt to make anki cards for me, and output as markdown codes in q and a format, so when i paste into mindmanager, it’s already in a parent-child format. I myself have a further macro to make this into anki thru ankiconnect. but let’s concentrate on the card’s quality.
it made quite many cards, some are not very significant/meaningful for medical students. for those that likely useful for exam, i highlighted them with a thumb.
chatgpt by default output 10-20 cards, depending on the text size you give it.
if you think it’s making too little, you can say not all content is used, ask it to make more (and repeat if you still want more).
there are many PDF-> anki service on web,
but most of them ask you to upload PDF of a whole BOOK.
for me, i work with 1 page of text each time, and i wanna tailor made the cards, so i do this way.
comments suggestions are appreciated. thanks
original text:
SUMMARY AND RECOMMENDATIONS ●Choice of treatment – Endometrial hyperplasia (EH) is categorized into two groups: EH without atypia and EH with atypia (also referred to as endometrial intraepithelial neoplasia [EIN]). EH may progress to, or coexist with, endometrial carcinoma. The choice of treatment (observation, progestin therapy, or hysterectomy) is based on several factors: type of EH (with or without atypia), menopausal status, desire for fertility, contraceptive needs, and risk factors present (table 2). (See ‘Introduction’ above and ‘Goal of management’ above.) ●EH without atypia – Untreated EH without atypia has a risk of progression to malignancy of approximately 10 percent or less over 20 years. (See ‘Natural history’ above.) •For most patients with EH without atypia, we suggest progestin therapy with endometrial sampling rather than hysterectomy (Grade 2C) (algorithm 1 and algorithm 2). Treatment with progestin therapy reduces the risk of progression to endometrial carcinoma to approximately 2 percent at 10 years. Observation is a reasonable alternative for premenopausal patients who have no risk factors for endometrial carcinoma (table 2) and/or who have contraindications to progestins. For postmenopausal patients with endometrial carcinoma risk factors and/or contraindications to progestins, we discuss surgical management with hysterectomy for definitive management. (See ‘Alternate for patients at low risk of progression: Observation’ above and ‘Preferred: Medical or surgical treatment’ above.) ●EH with atypia – Untreated EH with atypia has a risk of progression to endometrial carcinoma of up to 40 percent over 20 years, and coexistent endometrial carcinoma may be present in up to 40 percent of these patients. (See ‘Natural history’ above.) •For patients with EH with atypia who are postmenopausal or who are premenopausal and have completed childbearing, we recommend hysterectomy rather than progestin therapy with endometrial sampling (Grade 1B) (algorithm 4 and algorithm 3). •For premenopausal patients with EH with atypia who wish to preserve fertility, we suggest progestin therapy with endometrial sampling rather than hysterectomy (Grade 2B) (algorithm 4). (See ‘Preferred treatment: Hysterectomy’ above and ‘Alternate treatment: Progestin therapy’ above.) •For most patients undergoing hysterectomy as treatment for EH with atypia, we suggest hysterectomy without bilateral oophorectomy rather than with bilateral oophorectomy (Grade 2C). (See ‘Role of oophorectomy and salpingectomy’ above.) ●Progestin therapy – Common progestin treatments for EH (any type) include the levonorgestrel (LNG)-releasing intrauterine device (IUD [LNG 52 mg; Mirena, Liletta]), oral megestrol acetate, or oral medroxyprogesterone acetate (MPA (table 3)). Combined oral estrogen-progestin contraceptives (COCs) have not been well studied for EH treatment but are an option for some premenopausal patients. (See ‘Progestin therapy’ above.) •For most patients with EH (with or without atypia) undergoing medical management, we suggest the LNG 52 mg rather than systemic progestins (oral, intramural, subcutaneous, or transdermal (Grade 2B)). Studies have demonstrated that the LNG 52 mg compared with oral progestins for the treatment of EH is associated with higher regression rates and lower relapse rates. (See ‘Evidence of the efficacy of progestin therapy’ above and ‘Evidence of the efficacy of progestin therapy’ above and ‘Choice of progestin’ above.)
Before posting, please do the following:
- Search these forums.
- Read Getting Help.
- Try the steps in Troubleshooting.
- Check the FAQs.
- Check the Platform Notes.
If your problem persists, please delete this text, and explain the problem you are having in as much detail as possible.